$RMHI
Retrieve Medical Holdings, Inc.

2023 Q1 Form 10-Q Financial Statement

#000119983523000089 Filed on February 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $110.4K
YoY Change 112.08%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $110.4K
YoY Change 112.07%
Operating Profit -$110.4K
YoY Change 112.07%
Interest Expense $1.830K
YoY Change -79.28%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$112.2K
YoY Change 89.08%
Income Tax
% Of Pretax Income
Net Earnings -$112.2K
YoY Change 89.1%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.29
COMMON SHARES
Basic Shares Outstanding 78.36M shares 78.36M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $96.72K
YoY Change -48.43%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $5.760K
YoY Change 4.73%
Inventory
Prepaid Expenses $5.760K
Receivables
Other Receivables
Total Short-Term Assets $102.5K
YoY Change -46.92%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $102.5K
Total Long-Term Assets $0.00
Total Assets $102.5K
YoY Change -46.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $307.1K
YoY Change 55.68%
Accrued Expenses $125.7K
YoY Change 71.52%
Deferred Revenue
YoY Change
Short-Term Debt $10.00K
YoY Change 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $442.9K
YoY Change 57.84%
LONG-TERM LIABILITIES
Long-Term Debt $263.0K
YoY Change -11.74%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $263.0K
YoY Change -11.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $442.9K
Total Long-Term Liabilities $263.0K
Total Liabilities $705.9K
YoY Change 22.0%
SHAREHOLDERS EQUITY
Retained Earnings -$5.467M
YoY Change 4.15%
Common Stock $7.836K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$603.4K
YoY Change
Total Liabilities & Shareholders Equity $102.5K
YoY Change -46.92%

Cashflow Statement

Concept 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$112.2K
YoY Change 89.1%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$30.88K
YoY Change -29.17%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -$30.88K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -$30.88K
YoY Change -58.04%
FREE CASH FLOW
Cash From Operating Activities -$30.88K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2021Q4 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2021Q4 us-gaap Interest Paid
InterestPaid
usd
CY2022Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001452804
CY2022Q4 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2022Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q4 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q4 dei Entity File Number
EntityFileNumber
005-87668
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2022Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2022Q4 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
usd
CY2022Q4 dei Entity Registrant Name
EntityRegistrantName
PEAK PHARMACEUTICALS, INC.
CY2022Q4 pkph Proceeds From Repayments Of Convertible Notes Payable
ProceedsFromRepaymentsOfConvertibleNotesPayable
usd
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2022Q4 us-gaap Interest Paid
InterestPaid
usd
CY2022Q4 dei Document Type
DocumentType
10-Q
CY2022Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite A-1
CY2022Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1973257
CY2022Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
14201 N. Hayden Road
CY2022Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Scottsdale
CY2022Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
AZ
CY2022Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
85260
CY2022Q4 dei City Area Code
CityAreaCode
(480)
CY2022Q4 dei Local Phone Number
LocalPhoneNumber
659-6404
CY2022Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2022Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2022Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q4 dei Entity Shell Company
EntityShellCompany
true
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
78363567 shares
CY2022Q4 us-gaap Cash
Cash
96720 usd
CY2022Q3 us-gaap Cash
Cash
127599 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5760 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2750 usd
CY2022Q4 us-gaap Assets
Assets
102480 usd
CY2022Q3 us-gaap Assets
Assets
130349 usd
CY2022Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
199693 usd
CY2022Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
153681 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
307146 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
224548 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
125730 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
123955 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
10000 usd
CY2022Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
10000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
228000 usd
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
228000 usd
CY2022Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
35000 usd
CY2022Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
35000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
705876 usd
CY2022Q3 us-gaap Liabilities
Liabilities
621503 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78363567 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78363567 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78363567 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78363567 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7836 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
7836 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4855566 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4855566 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5466798 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5354556 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-603396 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-491154 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
102480 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
130349 usd
CY2022Q4 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
46012 usd
CY2021Q4 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
4770 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
110412 usd
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
52063 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
110412 usd
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
52063 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-110412 usd
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-52063 usd
CY2022Q4 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
882 usd
CY2021Q4 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
132 usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
1830 usd
CY2021Q4 us-gaap Interest Expense
InterestExpense
8831 usd
CY2021Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1539 usd
CY2022Q4 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-1830 usd
CY2021Q4 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-7292 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-112242 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-59355 usd
CY2022Q4 pkph Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
78363567 shares
CY2021Q4 pkph Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
78363567 shares
CY2022Q4 pkph Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.00
CY2021Q4 pkph Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.00
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-326185 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-59355 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-385540 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-491154 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-112242 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-603396 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-112242 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-59355 usd
CY2021Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1539 usd
CY2022Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3010 usd
CY2021Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-5500 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
36586 usd
CY2021Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6216 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
46012 usd
CY2021Q4 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-9090 usd
CY2022Q4 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1775 usd
CY2021Q4 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
38102 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30879 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43598 usd
CY2021Q4 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-20000 usd
CY2021Q4 pkph Proceeds From Repayments Of Convertible Notes Payable
ProceedsFromRepaymentsOfConvertibleNotesPayable
-10000 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-30000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30879 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-73598 usd
CY2022Q3 us-gaap Cash
Cash
127599 usd
CY2021Q3 us-gaap Cash
Cash
261152 usd
CY2022Q4 us-gaap Cash
Cash
96720 usd
CY2021Q4 us-gaap Cash
Cash
187554 usd
CY2022Q4 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zwy6kt0pSumg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zXiHYajPvqcj">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates made in connection with the accompanying consolidated financial statements include the valuation allowances against net deferred tax assets and accounting for convertible debt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
163655 shares
CY2021Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
271936 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3291000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3291000 shares
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5466798 usd
CY2022Q4 pkph Working Captial Deficiency
WorkingCaptialDeficiency
-603396 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-112242 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30879 usd
CY2022Q4 us-gaap Cash
Cash
96720 usd
CY2022Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
199693 usd
CY2022Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
153681 usd
CY2022Q4 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
46012 usd
CY2021Q4 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
4770 usd
CY2022Q4 pkph Disclosure Stock Options Details2 Abstract
DisclosureStockOptionsDetails2Abstract
<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureStockOptionsDetails2Abstract_zQvetjC86k3c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Number<br/> of Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Exercise Price per<br/> Share</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Average<br/> Remaining<br/> Term<br/> in Years</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">Outstanding December 31, 2022 and September 30, 2022</td><td style="width: 3%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_z5jnKyRK4Ad"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zHeLf0iZXwD5">375,000</span></span></td><td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zHXXMfEIELq5"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_ztUOBQixg0Xb">0.0067</span></span></td><td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxH_c20221001__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zdHf7V51Jdab" title="::XDX::P9M14D"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxH_c20211001__20211231__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zN8RtZ5cgipi" title="::XDX::P9M14D">0.79</span></span></td><td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">Exercisable, December 31, 2022 and September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zy0JLQ8zOfW8"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zh7RzOrvSXnl">375,000</span></span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_z0RvhsJhKOBc"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zHAuD0PaScne">0.0067</span></span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxH_c20221001__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_znT1IChUoll4" title="::XDX::P9M14D"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxH_c20211001__20211231__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zwbwrrhDLBw5" title="::XDX::P9M14D">0.79</span></span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001199835-23-000089-index-headers.html Edgar Link pending
0001199835-23-000089-index.html Edgar Link pending
0001199835-23-000089.txt Edgar Link pending
0001199835-23-000089-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pkph-20221231.xsd Edgar Link pending
pkph123122-10q.htm Edgar Link pending
pkph123122-ex31_1.htm Edgar Link pending
pkph123122-ex31_2.htm Edgar Link pending
pkph123122-ex32_1.htm Edgar Link pending
pkph123122-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
pkph-20221231_lab.xml Edgar Link unprocessable
pkph-20221231_pre.xml Edgar Link unprocessable
pkph123122-10q_htm.xml Edgar Link completed
pkph-20221231_cal.xml Edgar Link unprocessable
pkph-20221231_def.xml Edgar Link unprocessable